Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $181.33 Average Price Target from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average rating of “Buy” from the twenty-two research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, twenty have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $181.33.

A number of research firms have weighed in on SRPT. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Barclays cut their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Piper Sandler lowered their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th.

Sarepta Therapeutics Stock Down 3.0 %

NASDAQ SRPT opened at $109.11 on Tuesday. Sarepta Therapeutics has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The business has a fifty day moving average price of $124.21 and a two-hundred day moving average price of $132.49. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $10.42 billion, a PE ratio of 87.29 and a beta of 0.81.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of SRPT. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics in the first quarter worth $32,000. Huntington National Bank lifted its position in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the period. Nkcfo LLC bought a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $43,000. Finally, Riggs Asset Managment Co. Inc. boosted its holdings in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.